I am/have/had
I am looking for
Advanced Filters
Found 2 clinical trials
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
measurable disease
neutrophil count
adjuvant therapy
stage iv nsclc
dabrafenib
- 0 views
- 19 Feb, 2024
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
The purpose of this study is to develop a new drug treatment to reverse tumor resistance to radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors. This study is also being done to find out the highest doses of copanlisib and vemurafenib that, when given …
avid
malabsorption syndrome
measurable disease
neutrophil count
thyroid cancer (follicular cell)
- 0 views
- 19 Feb, 2024